Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Julphar
Harvard Business School
McKinsey
Merck
Cipla
Baxter
Farmers Insurance
Johnson and Johnson

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,241,244

« Back to Dashboard

Summary for Patent: 8,241,244
Title:Needleless injector drug capsule and a method for filling thereof
Abstract: A method for tilling needleless injector capsules with liquid drug, whereby dissolved gas within the drug is replaced by a less soluble gas in order to reduce the inclusion of gas bubbles, or to prevent the growth of bubbles during storage and thereby prevent breakage of the capsules.
Inventor(s): Henry; William (Trumpington, GB), Lewis; Andrew (Trumpington, GB)
Assignee: Zogenix, Inc. (Emeryville, CA)
Application Number:13/110,206
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,241,244

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,241,244

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0127942.1Nov 21, 2001

Non-Orange Book US Patents Family Members for Patent 8,241,244

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,663,158 Needleless injector drug capsule and a method for filling thereof ➤ Sign Up
8,118,771 Needleless injector drug capsule and a method for filling thereof ➤ Sign Up
8,491,524 Needleless injector drug capsule and a method for filling thereof ➤ Sign Up
8,241,243 Needleless injector drug capsule and a method for filling thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Fish and Richardson
Queensland Health
Chubb
McKesson
Mallinckrodt
Covington
Merck
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.